FDA approves Abecma for relapsed, refractory multiple myeloma
The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.
Oncology & Cancer
Researchers identify protein that controls CAR T cell longevity
CAR T cell therapy has revolutionized the way certain types of cancer are treated, and the longer those CAR T cells live in a patient’s body, the more effectively they respond to cancer. Now, in a new study, researchers at Children’s Hospital of Philad…
Looking at the environment around tumors could help predict how cancer spreads
Examining the immune cells in the environment around a tumor could help to predict how a person’s cancer might progress and respond to treatment, according to new research led by UCL and the Francis Crick Institute.
Unlocking the body’s hidden weapon against cancer: The role of broken chromosomes
Scientists have unraveled the mechanisms of the cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes (cGAS-STING) signaling pathway activated by micronuclei, as well as its significant effects on tumor immunity…
Novel mechanism supports antitumor response and T-cell survival
A recent Northwestern Medicine study has discovered a previously unknown molecular mechanism that supports antitumor responses and cell survival in cytotoxic immune cells, according to findings published in the Journal of Clinical Investigation.
Bispecific immune checkpoint inhibitor improves survival in gastric cancer patients regardless of PD-L1 status
The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free survival and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer, inclu…
Biologic drug-device combination immunotherapy for metastatic prostate cancer patients
SYNC-T, an investigational therapy that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug led to numerous clinical responses in patients with metastatic castrate-resistant prostate cancer …
Immunotherapies show promise for patients with kidney cancer and solid organ transplant recipients with skin cancer
Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings from two clinical trials in a plenary session highlighting advances in novel immunotherapy approaches at the American Association for Cancer Research (AAC…
Targeting vulnerability in B-cell development leads to novel drug combination for leukemia
Despite having an overall survival rate of 94%, B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer, can prove challenging to treat, with survival among relapsed or resistant cases falling between 30-50%.
Clinical trial data show investigational cancer vaccine may elicit lasting immune response in pancreatic cancer
New data presented by Memorial Sloan Kettering Cancer Center (MSK) researchers show an experimental approach to treating pancreatic cancer with the messenger RNA (mRNA)-based therapeutic cancer vaccine candidate, autogene cevumeran, continues to show p…